Last reviewed · How we verify
Reiferon Retard in Arm 1
Reiferon Retard in Arm 1 is a Interferon alfa-2a (long-acting/sustained-release) Biologic drug developed by MinaPharm Pharmaceuticals. It is currently FDA-approved for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas). Also known as: Pegylated interferon alfa-2a (Reiferon Retard 160 µg ®).
Reiferon Retard is a long-acting interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth.
Reiferon Retard is a long-acting interferon alfa-2a that activates innate and adaptive immune responses to inhibit viral replication and tumor cell growth. Used for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).
At a glance
| Generic name | Reiferon Retard in Arm 1 |
|---|---|
| Also known as | Pegylated interferon alfa-2a (Reiferon Retard 160 µg ®) |
| Sponsor | MinaPharm Pharmaceuticals |
| Drug class | Interferon alfa-2a (long-acting/sustained-release) |
| Target | Type I interferon receptor (IFNAR) |
| Modality | Biologic |
| Therapeutic area | Oncology, Virology |
| Phase | FDA-approved |
Mechanism of action
Interferon alfa-2a binds to type I interferon receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. The retard (sustained-release) formulation extends the half-life, allowing less frequent dosing while maintaining therapeutic interferon levels. This mechanism makes it effective against chronic viral infections and certain malignancies.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Headache
- Neutropenia
- Thrombocytopenia
- Depression/mood changes
- Thyroid dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reiferon Retard in Arm 1 CI brief — competitive landscape report
- Reiferon Retard in Arm 1 updates RSS · CI watch RSS
- MinaPharm Pharmaceuticals portfolio CI
Frequently asked questions about Reiferon Retard in Arm 1
What is Reiferon Retard in Arm 1?
How does Reiferon Retard in Arm 1 work?
What is Reiferon Retard in Arm 1 used for?
Who makes Reiferon Retard in Arm 1?
Is Reiferon Retard in Arm 1 also known as anything else?
What drug class is Reiferon Retard in Arm 1 in?
What development phase is Reiferon Retard in Arm 1 in?
What are the side effects of Reiferon Retard in Arm 1?
What does Reiferon Retard in Arm 1 target?
Related
- Drug class: All Interferon alfa-2a (long-acting/sustained-release) drugs
- Target: All drugs targeting Type I interferon receptor (IFNAR)
- Manufacturer: MinaPharm Pharmaceuticals — full pipeline
- Therapeutic area: All drugs in Oncology, Virology
- Indication: Drugs for Chronic hepatitis C
- Indication: Drugs for Chronic hepatitis B
- Indication: Drugs for Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)
- Also known as: Pegylated interferon alfa-2a (Reiferon Retard 160 µg ®)
- Compare: Reiferon Retard in Arm 1 vs similar drugs
- Pricing: Reiferon Retard in Arm 1 cost, discount & access